Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer

Oncotarget

Volumn 7, Issue 9, 2016, Pages 9815-9831

  Zhang, Xiaowei ^a   Hua, Ruixi ^b   Wang, Xiaofeng ^a   Huang, Mingzhu ^a   Gan, Lu ^a   Wu, Zhenhua ^a   Zhang, Jiejun ^a   Wang, Hongqiang ^c   Cheng, Yufan ^a   Li, Jin ^a   Guo, Weijian ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Zhoushan Hospital   (China)

Author keywords

Cancer stem cell; CD133; CD44; Gastric cancer; Stem cell marker

Indexed keywords

CD133 ANTIGEN; HERMES ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR SOX2; CD44 PROTEIN, HUMAN; GLI1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; POU5F1 PROTEIN, HUMAN; PROM1 PROTEIN, HUMAN; SMALL INTERFERING RNA; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PHENOTYPE; POSITIVE FEEDBACK; PROTEIN EXPRESSION; SPHEROID CELL; STEM CELL; STOMACH CANCER; TREATMENT FAILURE; TUMOR INVASION; ANIMAL; BIOSYNTHESIS; CANCER STEM CELL; CANCER TRANSPLANTATION; FLOW CYTOMETRY; GENETICS; METABOLISM; MORTALITY; MOUSE; MULTICELLULAR SPHEROID; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; SCID MOUSE; STOMACH TUMOR; TUMOR CELL CULTURE; XENOGRAFT;

AC133 ANTIGEN; ANIMALS; ANTIGENS, CD44; BIOMARKERS, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SOXB1 TRANSCRIPTION FACTORS; SPHEROIDS, CELLULAR; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; ZINC FINGER PROTEIN GLI1;

EID: 84959398233     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6890     Document Type: Article

References (56)

1. Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J and Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. CANCER RES. 2011; 71:1772-1780.
2. Wang T, Ong CW, Shi J, Srivastava S, Yan B, Cheng CL, Yong WP, Chan SL, Yeoh KG, Iacopetta B and Salto-Tellez M. Sequential expression of putative stem cell markers in gastric carcinogenesis. Br J Cancer. 2011; 105:658-665.
3. Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, Sentani K, Oue N and Yasui W. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. PATHOL INT. 2012; 62:112-119.
4. Nosrati A, Naghshvar F and Khanari S. Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma. Int J Mol Cell Med. 2014; 3:279-286.
5. Wang W, Dong LP, Zhang N and Zhao CH. Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis. INT J CLIN EXP MED. 2014; 7:5059-5066.
6. O'Brien CA, Kreso A and Jamieson CH. Cancer stem cells and self-renewal. CLIN CANCER RES. 2010; 16:3113-3120.
7. Harris PJ, Speranza G and Dansky UC. Targeting embryonic signaling pathways in cancer therapy. Expert Opin Ther Targets. 2012; 16:131-145.
8. Qiao XT and Gumucio DL. Current molecular markers for gastric progenitor cells and gastric cancer stem cells. J GASTROENTEROL. 2011; 46:855-865.
9. Zhang C, Li C, He F, Cai Y and Yang H. Identification of CD44+CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol. 2011; 137:1679-1686.
10. Rocco A, Liguori E, Pirozzi G, Tirino V, Compare D, Franco R, Tatangelo F, Palaia R, D'Armiento FP, Pollastrone G, Affuso A, Bottazzi EC, Masone S, et al. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors. J CELL PHYSIOL. 2012; 227:2686-2693.
11. Rocco A, Compare D and Nardone G. Cancer stem cell hypothesis and gastric carcinogenesis: Experimental evidence and unsolved questions. World J Gastrointest Oncol. 2012; 4:54-59.
12. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC. Identification of gastric cancer stem cells using the cell surface marker CD44. STEM CELLS. 2009; 27:1006-1020.
13. Qiu X, Wang Z, Li Y, Miao Y, Ren Y and Luan Y. Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. CANCER LETT. 2012; 323:161-170.
14. Jinesh GG, Choi W, Shah JB, Lee EK, Willis DL and Kamat AM. Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. CELL DEATH DIFFER. 2013; 20:382-395.
15. Vermeulen L, Sprick MR, Kemper K, Stassi G and Medema JP. Cancer stem cells-old concepts, new insights. CELL DEATH DIFFER. 2008; 15:947-958.
16. O'Brien CA, Pollett A, Gallinger S and Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. NATURE. 2007; 445:106-110.
17. Korkaya H and Wicha MS. Breast cancer stem cells: we've got them surrounded. CLIN CANCER RES. 2013; 19:511-513.
18. Clark PA, Iida M, Treisman DM, Kalluri H, Ezhilan S, Zorniak M, Wheeler DL and Kuo JS. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. NEOPLASIA. 2012; 14:420-428.
19. Broadley KW, Hunn MK, Farrand KJ, Price KM, Grasso C, Miller RJ, Hermans IF and McConnell MJ. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. STEM CELLS. 2011; 29:452-461.
20. Ohata H, Ishiguro T, Aihara Y, Sato A, Sakai H, Sekine S, Taniguchi H, Akasu T, Fujita S, Nakagama H and Okamoto K. Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells. CANCER RES. 2012; 72:5101-5110.
21. Botchkina GI, Zuniga ES, Das M, Wang Y, Wang H, Zhu S, Savitt AG, Rowehl RA, Leyfman Y, Ju J, Shroyer K and Ojima I. New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. MOL CANCER. 2010; 9:192.
22. Liu J, Ma L, Xu J, Liu C, Zhang J, Liu J, Chen R and Zhou Y. Spheroid body-forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties. INT J ONCOL. 2013; 42:453-459.
23. Chen T, Yang K, Yu J, Meng W, Yuan D, Bi F, Liu F, Liu J, Dai B, Chen X, Wang F, Zeng F, Xu H, et al. Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. CELL RES. 2012; 22:248-258.
24. Jiang Y, He Y, Li H, Li HN, Zhang L, Hu W, Sun YM, Chen FL and Jin XM. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. GASTRIC CANCER. 2012; 15:440-450.
25. Brungs D, Aghmesheh M, Vine KL, Becker TM, Carolan MG and Ranson M. Gastric cancer stem cells: evidence, potential markers, and clinical implications. J GASTROENTEROL. 2015.
26. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L and Ambudkar SV. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst. 2010; 102:1637-1652.
27. Lu RQ, Wu JG, Zhou GC, Jiang HG, Yu JW and Jiang BJ. [Sorting of CD133(+) subset cells in human gastric cancer and the identification of their tumor initiating cell-like properties]. Zhonghua Wei Chang Wai Ke Za Zhi. 2012; 15:174-179.
28. Lee HH, Seo KJ, An CH, Kim JS and Jeon HM. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer. J SURG ONCOL. 2012; 106:999-1004.
29. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. CELL. 2007; 131:861-872.
30. Song Z, Yue W, Wei B, Wang N, Li T, Guan L, Shi S, Zeng Q, Pei X and Chen L. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLOS ONE. 2011; 6:e17687.
31. Hsieh A, Ellsworth R and Hsieh D. Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells. J CELL PHYSIOL. 2011; 226:1118-1127.
32. Moon SH, Kim DK, Cha Y, Jeon I, Song J and Park KS. PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. INT J ONCOL. 2013; 42:921-928.
33. Li J, Wang G, Wang C, Zhao Y, Zhang H, Tan Z, Song Z, Ding M and Deng H. MEK/ERK signaling contributes to the maintenance of human embryonic stem cell selfrenewal. DIFFERENTIATION. 2007; 75:299-307.
34. Nolte SM, Venugopal C, McFarlane N, Morozova O, Hallett RM, O'Farrell E, Manoranjan B, Murty NK, Klurfan P, Kachur E, Provias JP, Farrokhyar F, Hassell JA, et al. A cancer stem cell model for studying brain metastases from primary lung cancer. J Natl Cancer Inst. 2013; 105:551-562.
35. Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, Chen KK, Lopez JP, Poon RT and Fan ST. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. HEPATOLOGY. 2010; 52:528-539.
36. Lin Y, Yang Y, Li W, Chen Q, Li J, Pan X, Zhou L, Liu C, Chen C, He J, Cao H, Yao H, Zheng L, et al. Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. MOL CELL. 2012; 48:627-640.
37. Katoh Y and Katoh M. Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. INT J ONCOL. 2009; 35:187-192.
38. Kim Y, Lee YS, Choe J, Lee H, Kim YM and Jeoung D. CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J BIOL CHEM. 2008; 283:22513-22528.
39. Hamanaka RB, Bennett BS, Cullinan SB and Diehl JA. PERK and GCN2 contribute to eIF2alpha phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. MOL BIOL CELL. 2005; 16:5493-5501.
40. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB and Rosen N. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. CANCER CELL. 2010; 18:39-51.
41. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S and Seitz S. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci U S A. 2012; 109:1655-1660.
42. Schmitt M, Metzger M, Gradl D, Davidson G and Orian-Rousseau V. CD44 functions in Wnt signaling by regulating LRP6 localization and activation. CELL DEATH DIFFER. 2015; 22:677-689.
43. Zhu X, Morales FC, Agarwal NK, Dogruluk T, Gagea M and Georgescu MM. Moesin is a glioma progression marker that induces proliferation and Wnt/beta-catenin pathway activation via interaction with CD44. CANCER RES. 2013; 73:1142-1155.
44. Bates RC, Edwards NS, Burns GF and Fisher DE. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. CANCER RES. 2001; 61:5275-5283.
45. Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlow B and Nestor M. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PLOS ONE. 2014; 9:e94621.
46. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, Xu W, Cui C, Xing Y, Liu Y, Cao B, Liu C, Wu G, et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci U S A. 2013; 110:6829-6834.
47. Zhang KZ, Zhang QB, Zhang QB, Sun HC, Ao JY, Chai ZT, Zhu XD, Lu L, Zhang YY, Bu Y, Kong LQ and Tang ZY. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. J HEMATOL ONCOL. 2014; 7:28.
48. Yu S, Cai X, Wu C, Wu L, Wang Y, Liu Y, Yu Z, Qin S, Ma F, Thiery JP and Chen L. Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression. Oncotarget. 2015; 6:2951-2965. doi: 10.18632/oncotarget.3095
49. Samardzija C, Quinn M, Findlay JK and Ahmed N. Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. J OVARIAN RES. 2012; 5:37.
50. Peng S, Maihle NJ and Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. ONCOGENE. 2010; 29:2153-2159.
51. Wang D, Zhu H, Zhu Y, Liu Y, Shen H, Yin R, Zhang Z and Su Z. CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stemlike cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer. ACTA HISTOCHEM. 2013; 115:349-356.
52. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. CANCER RES. 2010; 70:10433-10444.
53. Ahn HJ, Kim G and Park KS. Ell3 stimulates proliferation, drug resistance, and cancer stem cell properties of breast cancer cells via a MEK/ERK-dependent signaling pathway. Biochem Biophys Res Commun. 2013; 437:557-564.
54. Chang G, Wang J, Zhang H, Zhang Y, Wang C, Xu H, Zhang H, Lin Y, Ma L, Li Q and Pang T. CD44 targets Na(+)/H(+) exchanger 1 to mediate MDA-MB-231 cells' metastasis via the regulation of ERK1/2. Br J Cancer. 2014; 110:916-927.
55. Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JJ, Dunn GP, Bui JD, Sunwoo JB and Uppaluri R. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. CANCER RES. 2012; 72:365-374.
56. Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, Liu L, Jia D, Tian Q, Wu J, Ye Y, Wang Q, Long Z, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. CLIN CANCER RES. 2011; 17:7574-7583.